Online inquiry

IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14568MR)

This product GTTS-WQ14568MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL), B cell acute lymphoblastic leukemia (B cell ALL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14568MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11540MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ3920MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ2259MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ10010MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ6217MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ402MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ50MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ4406MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-663513
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW